You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.
The company said it plans to use the net proceeds for working capital and general corporate purposes.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
The company said it will use the proceeds from the offering for working capital and general corporate purposes, among other things.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.
The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.